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ABSTRACT 
 
The tyrosine kinase receptor protein c-kit exerts a broad range of activities during 
organogenesis and normal cell development. It is involved in the development of multiple 
haematopoietic cell lines, mast cells, melanogenesis, interstitial cells of Cajal and 
gametogenesis. Recent studies have revealed that over-expression of c-kit protein occurs 
in a narrow subset of malignant neoplasms, including gastrointestinal stromal tumors, 
myeloid leukemias, seminomas and adenoid cystic carcinomas (ACC). C-kit reportedly is 
not expressed in polymorphous low-grade adenocarcinoma (PLGA). 
 
 
We examined the expression of the c-kit antigen in the malignant salivary gland 
neoplasms ACC and PLGA and compared it to its expression in the benign salivary gland 
tumor monomorphic adenoma (including trabecular adenoma, canalicular adenoma and 
basal cell adenoma).  
Formalin-fixed paraffin-embedded sections of 49 salivary gland neoplasms (17 
monomorphic adenomas, 17 PLGA and 15 ACC) accessioned between 1989 and 2002 
were retrieved from the files of the Department of Pathology, Long Island Jewish 
Medical Center, New Hyde Park, NY, and were stained with an anti-c-kit polyclonal 
antibody. 
 
C-kit reactivity was uniformly positive in the cytoplasm of luminal neoplastic cells in 
ACCs (15/15, 100%). Positive reactivity was also identified in the majority of PLGAs 
(16/17, 94%), with at least 25% of the tumor cells being positive. Similar reactivity was 
seen in monomorphic adenomas (16/17, 94%). In the normal surrounding salivary gland 
tissue, c-kit reactivity was identified only focally in ductal epithelium. 
 
In contrast to previous reports, we find that c-kit expression was not restricted to ACC 
but was expressed in all three tumor types evaluated (ACC, PLGA and monomorphic 
adenoma). Therefore, c-kit does not appear to be an ideal marker for distinguishing 
between ACC and PLGA in equivocal cases, or benign from malignant salivary gland 
neoplasms.  
 
 
INTRODUCTION 
 
The transmembrane tyrosine kinase receptor c-kit (CD117) is a 145 to 165 kD proto-
oncogene that is structurally related to the platelet-derived growth factor (PDGF) receptor 
and the colony stimulatory factor (CSF) receptor1. Binding of its ligand (alternatively 
known as steel factor, stem cell factor, and mast cell growth factor) promotes 
phosphorylation, which subsequently activates a signaling cascade that regulates cell 
growth and development. 
 
C-kit is expressed in a range of normal developmental pathways, including hematopoiesis 
and spermatogenesis. It is required for the normal migration and development of germ 
cells and melanocytes1. It has been shown that mice bearing mutations in this gene locus 
are characterized by severe macrocytic anemia, lack of pigmentation and sterility. 
 
In normal human tissue, c-kit is expressed in melanocytes, breast epithelium cells, mast 
cells2, and the interstitial cells of Cajal3, which initiate and propagate slow muscle 
activity in gastrointestinal muscles. 
 
Over-expression of this tyrosine kinase receptor has been reported in a subset of 
malignant neoplasms such as gastrointestinal stromal tumors (GIST)4, myeloid leukemia, 
testicular germ cell tumors5, endometrial carcinomas, papillary and follicular thyroid 
carcinomas5, renal and hepatic angiomyolipoma6, synovial sarcoma7, osteosarcoma7 and 
Ewing’s sarcoma7. 
 
In human salivary gland neoplasms, reports of c-kit expression have been contradictory. 
Several reports have suggested that c-kit is expressed in ACC. It is reportedly absent in 
PLGA1,8,9. Based on these findings, it has been suggested that c-kit expression may be a 
suitable immunohistochemical marker to aid in distinguishing between these two 
neoplasms. 
 
The purpose of this study was to compare the extent of c-kit immunoreactivity in adenoid 
cystic carcinoma, polymorphous low-grade adenocarcinoma and monomorphic adenoma. 
 
MATERIALS AND METHODS 
 
Formalin-fixed paraffin-embedded sections of 49 salivary gland neoplasms (17 
monomorphic adenomas, 17 PLGA and 15 ACC) accessioned between 1989 and 2002 
were retrieved from the files of the Department of Pathology, Long Island Jewish 
Medical Center. 
 
The H&E stained slides were independently reviewed by three experienced pathologists 
(RK, JF, TB) and agreement was reached on all cases included in this study using 
accepted criteria10. 
 
Microwave heat-induced epitope retrieval (750 W microwave at medium power, 30 
minutes) was performed using the Trilogy™ system (Cell Marque, Hot Springs AK) as 
per the manufacturer’s directions and then treated with anti-human c-kit polyclonal 
antibody (Dako, Kyoto, Japan) at a 1:100 dilution. 
 
The antibody-antigen complex was detected using an indirect biotin-avidin system as per 
the manufacturer’s instructions (Ventana Basic DAB Detection Kit™, Ventana Medical 
Systems, Tucson AZ). 
 
Large cell undifferentiated lung carcinoma was used as positive controls for the c-kit 
marker. Normal salivary gland tissue was used as the negative control. 
 
Immunoreactivity was independently assessed by all study participants. Agreement was 
reached on all 49 specimens examined. Immunoreactivity was considered positive if 
greater than 10% of the tumor cells stained and was graded as weak (10-25%), mild (26-
50%), moderate (51-75%) and strong (76-100%). 
 
RESULTS 
 
The ACC group, comprising 12 women and 3 men, had a median age of 65 years (range: 
37-89 years). The tumor group included 8 lesions of minor salivary gland origin (4 palate, 
3 soft tissue of the neck, 1 maxillary sinus) and 7 lesions of major gland origin (5 parotid, 
2 submandibular gland). 
The median age of the PLGA group was 67 years (range: 38-73 years) and consisted of 
13 female patients and 4 male patients. All tumors arose from minor salivary gland tissue, 
primarily palate (8) and buccal mucosa (4), except for one of parotid origin. 
The monomorphic adenoma group, comprising 14 women and 3 men, had a median age 
of 66 years (range: 41-97). The tumors were located in the upper lip (9), parotid (4), 
buccal mucosa (3), and hard palate (1). 
 
C-kit expression (Table 1) was evident in 15/15 ACCs as indicated by positive 
immunoreactivity. Cytoplasmic staining was identified in the luminal neoplastic cells in 
ACC (Fig.1). C-kit expression was more prominent in solid variants of ACC. The 
intensity of staining was strongest in ACCs of minor salivary gland origin (Table 2). 
 
Positive reactivity was also noted in the majority of PLGAs (16/17, 94%) with at least 
25% of the tumor cells being positive (Table 1, Fig.2). However, there was variable 
immunoreactivity, ranging from faint focal to strong positivity. The overall intensity of 
staining was weaker in PLGA as compared to ACC. 
 
Similar positive immunoreactivity (16/17, 94%) was identified in monomorphic 
adenomas (Table 1, Fig.3). Expression was primarily noted in the luminal cells as in 
ACC, but the overall intensity was weaker than in ACC.  
 
In the normal surrounding salivary gland tissue, c-kit reactivity was focally detected in 
the ductal epithelium. 
 
 
 
DISCUSSION 
 
Overlapping features of infiltrating tubular and solid growth patterns combined with a 
tendency for perineural invasion can make the light microscopic distinction between 
PLGA and ACC challenging. In addition, canalicular and basal cell adenomas 
(monomorphic adenomas) can bear a striking resemblance to ACC, especially when 
examining tissue obtained from small or fragmented incisional biopsies.  
 
This study attempts to identify a highly specific immunohistochemical marker to 
distinguish between these entities, which to date has proven elusive. 
 
C-Kit Expression in ACC, PLGA and Monomorphic Adenoma 
 
In this study, the results showed that c-kit expression was not restricted to ACC but was 
significantly expressed in all three tumor types evaluated.  
 
Our finding that c-kit expression is positive in all ACCs examined is in agreement with 
previously published results11, 12, which reported that c-kit expression is highly positive in 
ACC, particularly solid variants13, 14.  
 
The intensity of staining is also of interest. In our study, strong staining (>75% of 
neoplastic cells) was identified in 43 % of ACCs of major salivary gland origin compared 
with 100 % of ACCs of minor salivary gland origin. In contrast, Oprea et al15 reported 
that expression was lower in ACC arising in minor salivary glands as opposed to major 
salivary gland ACCs, whereas Holst14 found no difference. Since c-kit reactivity is 
strongest in solid variants of ACC, variations in the predominant subtypes of ACC in 
different studies could account for these differences. In our study, there was a 
predominance of solid variant ACC in the minor salivary gland subgroup. 
 
Published reports of c-kit immunohistochemical reactivity in ACC have been 
contradictory.  
In an abstract comparing staining between ACC and PLGA, Penner et al8 reported 
cytoplasmic c-kit expression in 6 of 6 ACCs from major and minor salivary glands, but 
only 1 of 3 polymorphous low-grade adenocarcinomas (PLGAs). In a subsequent 
manuscript9, they identified weak c-kit immunoreactivity in 8/14 (57%) PLGAs. The 
intensity of c-kit staining was reportedly much stronger in ACC as compared to PLGA. 
Jeng et al1 found moderate to strong c-kit expression in ACC (3/4 tubular ACC, 8/17 
cribriform ACC and 4/4 solid ACC), but no expression in PLGA (0/4).  
In contrast, our results concur with the findings of Cohn et al16. They reported that ACC 
(8/8) and PLGA (7/8) demonstrated similar immunostaining patterns, with strong 
immunoreactivity in both neoplasms. 
 
The contradictory and disparate c-kit immunostaining results seen in PLGA are similar to 
the often divergent results reported between different studies of c-kit expression in soft 
tissue tumors17. These differences are likely due in part to the limited number of cases 
examined in individual reports and to variations in the experimental protocols and 
antibodies employed. Hornick and Fletcher17 concluded that variations in 
immunohistochemical technique could lead to major discrepancies in positive staining.  
 
Jeng et al1 employed a pressure cooker for epitope retrieval and used a different 
polyclonal anti-c-kit antibody (Medical and Biological Laboratories, Nagoya, Japan) than 
was used in this study (Dako, Kyoto, Japan). The Dako anti-c-kit antibody, used at a 
dilution of 1:100 in this study, reportedly has low background staining and is the 
antibody specified in the multi-center trial of Gleevec chemotherapy in GIST17. Penner et 
al9 also used the Dako antibody, but at a lower concentration (1:200) and with a pressure 
cooker for epitope retrieval. 
 
No published studies to date have compared expression of c-kit in ACC or PLGA to the 
benign salivary gland neoplasm monomorphic adenoma. In our present study, we found 
no evidence of  differences in c-kit staining between these neoplasms. 
 
Selective Immunohistochemical Markers in ACC, PLGA and Monomorphic Adenoma 
Other immunohistochemical markers have been reported to be of possible benefit in 
distinguishing between ACC, PLGA and monomorphic adenoma.  
 
It has been reported18 that S-100 immunoreactivity may be of value in differentiating 
ACC from PLGA. Although S-100 is positive in both neoplasms, staining is reportedly 
more diffuse and stronger in PLGA as compared to ACC. Strong S-100 and weak actin 
staining of PLGA compared to weak S-100 and moderate actin staining of ACC may aid 
in separating these two entities18. 
 
Araujo et al19, comparing cribriform areas of PLGA and ACC, reported that in contrast to 
ACC, the neoplastic luminal cells in cribriform areas of PLGA were positive for 
cytokeratin and integrin markers. 
 
Skalova et al20 reported a higher MIB1 (Ki-67 nuclear proliferation marker) index, in 
ACCs (21.4%) as compared to PLGAs (2.4%). The combination of MIB1, S-100 and 
Bcl-2 reportedly21 allows differentiation of ACC from PLGA. 
 
Prasad et al22 compared the immunoreactivity of ACC, PLGA and canalicular adenomas 
with the monoclonal antibodies α-smooth muscle actin, smooth muscle myosin heavy 
chain and calponin and concluded that the consistently positive staining pattern in ACCs 
may be diagnostically useful in discriminating histologically similar but consistently 
negative PLGAs and canalicular adenomas. A separate study23 reported that the anti-
muscle actin antibody HHF35 stained tubular and cribriform patterns of ACC, but solid 
variants of ACC. 
 
Glial fibrillary acidic protein (GFAP) is an intermediate filament cytoplasmic protein 
found in normal and neoplastic glial cells. Curran et al24 concluded that although not all 
monomorphic adenomas are positive for GFAP, the presence of GFAP reactivity at the 
tumor/connective tissue interface is specific for monomorphic adenoma. 
GFAP does not appear to be of value in discriminating between ACC and PLGA25, since 
both of these neoplasms tend to be consistently negative for c-kit immunoreactivity26. 
 
 
CONCLUSION 
 
C-kit reactivity was uniformly positive in the cytoplasm of luminal neoplastic cells in all 
ACCs examined. Positive reactivity was also identified in the majority of PLGAs and 
monomorphic adenomas. In the normal surrounding salivary gland tissue, c-kit reactivity 
was identified only focally in ductal epithelium. 
 
Of potential therapeutic interest is the recent observation that the tyrosine kinase inhibitor 
Gleevec (Imatinib mesylate, formerly STI571, Novartis Pharmaceuticals, Switzerland) 
appears to be effective in the treatment of gastrointestinal stromal tumors27. Gleevec 
inhibits the kinase activity of the normal c-Abl gene product, the oncogenic Bcr-Abl 
fusion protein involved in the pathogenesis of chronic myeloid leukemia, the platelet-
derived growth factor receptor as well as ligand-independent c-kit phosphorylation28.   
 
Whether Gleevec will prove effective as an adjunct in treating ACCs, which generally 
have a very poor long-term prognosis, remains to be determined. Unlike gastrointestinal 
stromal tumors, in which c-kit gain-of-function mutations of the juxtamembrane domain 
of exon 11 are noted, and mast cell tumors, in which mutations in the tyrosine kinase 
domain of exon 17 have been identified, both Holst et al14 and Jeng et al1 failed to 
identify similar mutations in c-kit positive salivary gland neoplasms examined. This 
might argue against a potential therapeutic benefit from Gleevec-based chemotherapy. 
 
In summary, we find that in contrast to previous reports, c-kit expression was not 
restricted to ACC but was expressed in all three tumor types evaluated (ACC, PLGA and 
monomorphic adenoma). Therefore, c-kit does not appear to be an ideal marker for 
distinguishing between ACC and PLGA in equivocal cases, or benign from malignant 
salivary gland neoplasms. These markers lack the specificity required to be of routine use 
in daily pathology practice.  
 
 ADENOID CYSTIC 
CARCINOMA 
POLYMORPHOUS LOW 
GRADE 
ADENOCARCINOMA 
MONOMORPHIC 
ADENOMA 
    
Total number of 
samples 
15 
 
17 17 
Negative staining 
 
0 1 1 
Weak staining 
(10-25% of cells) 
0 
 
4 1 
Mild staining 
(26-50%) 
1 
 
4 1 
Moderate staining 
(51-75%) 
3 
 
3 4 
Strong staining  
(76-100%) 
11 
 
5 10 
%  samples with 
positive staining 
100% 94% 94% 
 
 
Table 1:  Summary of c-kit staining results 
 
 
 
 MAJOR 
SALIVARY 
GLAND ORIGIN 
MINOR SALIVARY 
GLAND ORIGIN 
   
Total number of 
samples 
7 
 
8 
Negative staining 
 
0 0 
Weak staining 
(10-25% of cells) 
0 
 
0 
Mild staining 
(26-50%) 
1 
 
0 
Moderate staining 
(51-75%) 
3 
 
0 
Strong staining  
(76-100%) 
3 
 
8 
%  samples with 
>75% staining 
43% 
 
100% 
 
 
Table 2:  Summary of c-kit staining in Adenoid Cystic 
Carcinoma by origin: major salivary gland versus 
minor salivary gland origin 
Figure 1: Adenoid Cystic Carcinoma (H&E and c-kit, 200X). 
 
 
Figure 1: Adenoid Cystic Carcinoma (H&E and c-kit, 200X). 
 
Figure 2: Polymorphous Low Grade Adenocarcinoma (H&E and c-Kit, 100X) 
 
 
 
Figure 2: Polymorphous Low Grade Adenocarcinoma (H&E and c-Kit, 100X) 
Figure 3: Monomorphic Adenoma (H&E and c-kit, 100X). 
 
Figure 3: Monomorphic Adenoma (H&E and c-kit, 100X). 
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